Actinium Pharmaceuticals, Inc.
ATNM
$1.52
-$0.03-1.94%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 231.77% | -4.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 121.69% | -40.44% | |||
| Operating Income | -121.69% | 40.44% | |||
| Income Before Tax | -139.60% | 42.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -139.60% | 42.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -139.60% | 42.50% | |||
| EBIT | -121.69% | 40.44% | |||
| EBITDA | -120.48% | 39.89% | |||
| EPS Basic | -139.63% | 42.73% | |||
| Normalized Basic EPS | -139.71% | 42.76% | |||
| EPS Diluted | -139.63% | 42.73% | |||
| Normalized Diluted EPS | -139.71% | 42.76% | |||
| Average Basic Shares Outstanding | -0.03% | 0.43% | |||
| Average Diluted Shares Outstanding | -0.03% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||